November 6, 2020, Shanghai—Abbisko Therapeutics Co., Ltd. (“Abbisko” hereafter) is pleased to announce the appointment of Mr. Ye Lin as Chief Financial Officer and Head of Strategy of the Company. Mr. Ye will report to Dr. Yao-Chang Xu, Chairman and CEO of Abbisko. He will lead capital markets transactions, strategic financial planning, financial reporting and compliance, as well as future financing including public listing and other related matters.

“We are thrilled that Mr. Ye Lin is joining the executive team of Abbisko. He brings over 25 years’ experience in biopharmaceutical and investment industry, with a proven track record in investment banks and multinational pharmaceutical and biotech companies,” said Dr. Yao-Chang Xu, “Powerful financial strategies are crucial to Abbisko at present in support of its rapid expansion. We believe that Mr. Ye's extensive international experience of leading and financial management will further support Abbisko as it continues to grow its sustainable and diversified global business and in achieving its strategic growth ambitions..”

Prior to joining the Company, Mr. Ye Lin served as the CFO of Cstone Pharmaceuticals, responsible for its initial public offering (IPO) at Hong Kong Stock Exchange, financial capital market strategies, risk control and other related activities. Before joining Cstone, Mr. Ye held the Managing Director role and Head of Asia Healthcare Research in Goldman Sachs for years, overseeing Asian healthcare research spanning from Japan, Greater China, India to Australia. Prior to that, Mr. Ye specialized in the analysis of the biotechnology industry at the U.S. headquarter of Citigroup. Before entering the financial industry, Mr. Ye worked in Wyeth Pharmaceuticals, engaged in the product market analysis in Global New Product Marketing Group. He also served Amgen, focusing on drug discovery.

Mr. Ye Lin has a Master of Business Administration degree in Johnson Graduate School of Management from Cornell University, and a Master of Science (M.Sc.) degree in Medical Biophysics from the Ontario Cancer Institute of University of Toronto, and a Bachelor of Science (B.Sc.) degree in Biochemistry from University of Manitoba.

“Abbisko is dedicated to developing immuno-oncology and target-based therapies for novel and high potential targets, to develop first-in-class or best-in-class molecular entities,” said Mr. Ye Lin, “I am extremely impressed by Abbisko’s highly-differentiated, globally competitive product pipeline, as well as its resolution of solving unmet medical needs in China and around the world. I am excited to join such an excellent team in contributing to the Company's strategic transformation and future development. "